000010092 001__ 10092
000010092 005__ 20240125143602.0
000010092 0247_ $$2DOI$$a10.6083/c247ds915
000010092 037__ $$aIR
000010092 245__ $$aEffect of lab timing on detection of toxicities in patients Undergoing 177Lu-dotatate treatment for neuroendocrine tumors
000010092 260__ $$bOregon Health and Science University
000010092 269__ $$a2023
000010092 336__ $$aCapstone
000010092 502__ $$gMedicine (Undergraduate Medical Education)
000010092 502__ $$bM.D.
000010092 520__ $$aFor patients receiving Lu-DOTATATE therapy (four cycles every 8 weeks) for treatment of neuroendocrine tumors: does timing of laboratory assessment between treatment cycles have an impact on proportion of patients that must continue therapy at a reduced dose? And/or the proportion of patients that must postpone a subsequent infusion, or proportion of patients that must discontinue the therapy?
000010092 540__ $$fCC BY
000010092 650__ $$aNuclear Medicine$$023036
000010092 650__ $$aLutetium$$021663
000010092 650__ $$aTheranostic Nanomedicine$$011326
000010092 6531_ $$alab timing
000010092 6531_ $$aradionuclide therapy
000010092 691__ $$aSchool of Medicine$$041369
000010092 7001_ $$aMeeker, Laura$$uOregon Health and Science University$$041354
000010092 7201_ $$aMittra, Erik$$uOregon Health and Science University$$041354$$7Personal$$eMentor
000010092 8564_ $$9f7ea1748-88c2-45a1-9313-593ce40d114a$$s410233$$uhttps://digitalcollections.ohsu.edu/record/10092/files/Meeker.Laura.2023.pdf
000010092 905__ $$a/rest/prod/c2/47/ds/91/c247ds915
000010092 909CO $$ooai:digitalcollections.ohsu.edu:10092$$pstudent-work
000010092 980__ $$aScholarly Project Capstones